The final analysis (n=82) included 67 individuals with psoriasis receiving therapeutic immunosuppression, including methotrexate (n=14), TNF inhibitors (n=19), IL-17 inhibitors (n=14), IL-23 inhibitors (n=20), and 15 healthy volunteers (the control group). Here, IL23A is linked to psoriasis.